AZD7594

Phase 2Small molecule

AstraZeneca

AZD7594 is one of 31 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

COPDActive, not recruiting

AsthmaPhase 1

Active, not recruiting

COPDPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 2

Cinqair

Teva

Preclinical

13 3

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 4

Spiriva

Boehringer Ingelheim

Preclinical

8 5

AZD7594

AstraZeneca

Phase 2

3 6

Formoterol Fumarate

AstraZeneca

Preclinical

8 7

Atrovent

Boehringer Ingelheim

Preclinical

2 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics3 trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02645253·27 enrolled

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01636024·73 enrolled

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02648438·30 enrolled

Asthma3 trials

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03622112·808 enrolled

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03976869·36 enrolled

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02479412·54 enrolled

Drug2 trials

A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02967159·14 enrolled

A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04072562·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for AZD7594. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD7594 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD7594. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD7594

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics3 trials

Asthma3 trials

Drug2 trials

References

Drug Info

Quick Facts

Related News